24 February 2026

Chemicals Sector Review – Q3FY26

Gradual recovery, Divergent pricing, Select upside

Sensex: 83,294

Nifty: 25,713

Volumes recover, pricing uneven, trade tailwinds emerging: The chemical companies in our coverage universe reported revenue/EBITDA growth of 14/18% y/y (down 2/7% q/q) in Q3FY26. Commentary across domestic chemicals universe indicates a gradual volume-led recovery with pricing still uneven. US tariff normalization is a near-term positive for export-exposed names, while EU FTA and China anti-involution represent medium-term structural tailwinds, contingent on execution and enforcement. The sector narrative is shifting from pure destocking to early-cycle normalization, though China-linked pricing pressure persists in multiple chains.

Selective strength now; Q4 to test broader rebound: In Q3FY26, the CDMO and fluorochemical-led players delivered earnings beat, while agro and pigment-exposed players lagged amid pricing pressure and destocking. Refrigerants/CDMO earnings remain in a multi-quarter upcycle with others still in early recovery, as visibility improves but numbers lag. Q4FY26 is shaping up better with (a) SRF expecting improvement on pent-up agro orders; (b) Jubilant Ingrevia seeing pricing catalysts (B3; Acetyls); (c) NOCIL's 3-4% FY26 volume guidance implies a sharp rebound in Q4FY26 (>12% growth) on resilient domestic demand; (d) Sudarshan Chemicals expecting pigment recovery as destocking eases; and (e) Galaxy Surfactants seeing gradual improvement, as reformulation ramps-up.

Capex phases diverge; Inflection near for select names: The sector is in three capex phases: (a) peak investment; (b) ramp-up; and (c) harvest. SRF's Rs22-23bn FY26 and strong outlook for FY27 given large Odisha commitment ahead; Fine Organics entered a major capacity unlock phase with India SEZ and US Phase-I projects; NOCIL is in capex phase (TDQ expansion); Jubilant Ingrevia's Rs20bn capex cycle nearing completion (Rs5bn FY27); Aarti Industries is at the end of its cycle (~Rs11bn FY26 peak), awaiting the next earnings leg and Navin Fluorine is in the harvest mode post heavy investments. On risk-reward, Navin Fluorine and Jubilant appear best positioned given execution visibility and utilisation-led upside.

CY26 for Global Companies - Stabilization, Not Acceleration: Globally, CY26 is shaping up as a year of gradual normalization rather than a broad demand rebound, with the companies prioritizing cash generation, cost control and deleveraging. Dow Inc. highlighted a largely unchanged demand backdrop, with packaging relatively stable (aided by ~5% ethylene capacity rationalization) but infrastructure and mobility remain weak. Celanese and Eastman flagged continued acetate tow destocking. In contrast, Chemours reported strong Opteon refrigerant growth, underscoring refrigerants as a structural bright spot, mirroring fluorochemical strength seen in India.

Top Picks: Fine Organic Industries, Jubilant Ingrevia

Nitesh Dhoot
Research Analyst

Tanvi Warekar
Research Associate

Surbhi Nahar
Research Associate

Top Picks

Fine Organic Industries (FINEORG)

- FINEORG is undergoing a significant capacity expansion with the India SEZ (JNPT) and US Phase-I projects set to commercialise 18-24 months post the Apr-25 EC, unlocking saturated domestic sites for higher-value products.
- The SEZ land parcel exceeds all existing sites combined, while the US parcel is 5x larger, providing long-term scale visibility. With US approvals in place, Phase-I is de-risked, paving the way for a faster Phase-II. Global validations support onboarding larger customers and deeper wallet share.
- The US, ~26% of global additives market (vs. India's <4%), offers a strong localization opportunity given strict manufacturing date norms limiting ocean freight viability.
- Despite near-term utilisation constraints, end-FY27/early-FY28 capacity addition underpins a multi-year growth runway.
- Expansion is largely self-funded, supported by ~Rs13bn cash and ~Rs9bn expected FY26-27 cash generation (with project debt as needed).
- At 28/24x FY27/28e EPS trough multiples, we maintain BUY rating on the stock with a 12-month TP of Rs6,400, valuing it at 34x FY28e EPS.
- **Key Risks:** (a) US execution; (b) SEZ timelines; (c) and input volatility.

Jubilant Ingrevia (JUBLINGR)

- JUBLINGR's growth pivot is anchored in a structural mix shift towards higher-margin Specialty Chemicals (~Rs20bn revenue) and Nutrition (~Rs7bn), with Fine Chemicals and CDMO expected to form ~two-thirds of Specialty by FY27, reducing dependence on Pyridine.
- Human-grade Vitamin-B3 adds ~Rs2bn of high-margin revenue, moderating cyclicality. CDMO has emerged as the core growth engine, with 16 confirmed molecules (~Rs14bn peak potential) and 100+ pipeline opportunities; a large agro contract (~Rs5bn annually) is slated to reach full run-rate by Q1FY27. CDMO revenue is guided to scale from ~Rs3bn in FY26 to ~Rs12bn by FY28, delivering >Rs2.5bn EBITDA.
- Organizational overhaul (70–80% leadership refresh) and R&D expansion (100 to 150) support execution, backed by capacity addition and ~Rs6bn annual capex.
- With expected RoCE of >15% by FY27-28e, current valuation at ~14.4/11.4x FY27/28 EV/EBITDA appears undemanding. We maintain BUY rating on the stock with an SOTP-based TP of Rs975 (implied FY28 17.5x E/EBITDA).
- **Key Risks:** (a) Specialty/CDMO execution; (b) B3 ramp-up; and (c) acetyl downcycle persistence.

Trade tailwinds strengthen

US Tariffs Rollback and Replacement u/s 122

- Rollback of US IEEPA tariffs and their replacement under Section 122 has reduced India's effective US tariff burden to 15%, with Annex-II exemptions (including pharma APIs, select chemical intermediates and energy-linked inputs) largely retained.
- While many molecules saw partial relief under Annex-II, others still had some tariff impact earlier, making the shift incrementally positive for export-oriented chemical players i.e., Aarti, SRF, NFIL and NOCIL.
- The key monitorable is the expiry of Section 122 on July 24, 2026, after which tariff outcomes will hinge on fresh Section 301 actions.

EU-India Free Trade Agreement

- **Market size & access:** The EU is a ~€635bn chemicals market (turnover), while India exports only $9bn currently. With >90% of Indian goods exports becoming duty-free over time, addressable opportunity expands meaningfully.
- **Tariff impact:** EU chemical import duties of up to 12.8% move to near-zero under the FTA (tariffs are in the range of zero to 6.5%, while some specific categories i.e., cosmetics are up to 12.8%), delivering a ~5-10% pricing advantage to Indian exporters vs. non-FTA suppliers.
- **Export opportunity:** Chemicals form ~15% of India's EU exports and export volume for compliant players could scale materially over 5-7 years, led by specialty, agro intermediates and pharma chemicals.
- **China+1 tailwind:** The EU sources ~13% of chemicals from China; even a small sourcing shift creates a significant opportunity for India (currently <3% of EU's sourcing).
- **Investment & partnerships:** The EU is India's second largest chemical trade partner, and the deal should accelerate FDI, JVs and long-term contracts, especially in specialty chemicals and CDMO.
- **Risks & filters:** REACH and ESG compliance may act as a barrier, but they favour the organized players, while higher EU imports into India remain limited to niche segments.
- **Our view:** The deal is structurally positive for Indian chemicals, with winners being export-oriented players focused on specialty and value-added chemistries. Companies having relatively higher EU exposure: SRF, Navin Fluorine, Jubilant Ingrevia, Vinati Organics

Fig 1 – EU Chemical Imports – China vs India Share Comparison

EU's Chemical Imports		China Share %			India Share %		
HS Code	Product Category	FY24	FY25	YTDFY26	FY24	FY25	YTDFY26
28	Inorganic Chemicals	10.8	10.7	12.0	1.1	1.5	2.0
29	Organic Chemicals	11.7	11.8	12.0	3.3	3.2	3.0
32	Dyes, Pigments, Paints	12.2	10.4	10.4	4.1	4.4	4.2
33	Essential oils and resinoids, perfumery, cosmetic	6.2	6.6	6.8	1.9	1.9	1.8
34	Soaps, Surfactants, Lubricants, etc	8.6	9.8	10.7	0.6	0.6	0.7
38	Misc. Chemicals	12.6	13.6	22.6	2.0	2.0	2.3
	Overall	**11.3**	**11.4**	**13.0**	**2.7**	**2.7**	**2.7**

Source: Industry, Anand Rathi Research, ^Share in imports - Inter EU trade eliminated

Fig 2 – Indian Chemical Companies - US & EU Revenue Exposure

Company name	Sales (Rs m) FY25	Total Exports %	Europe %	EU %	US %	US % (Net of Exempted list)
Aarti Industries	72,713	60%	14%	14%	16%	15%
Atul	55,833	39%	8%	6%	8%	3%
Clean Science	9,666	61%	13%	13%	5%	0%
Fine Organic Industries	22,691	57%	10%	10%	18%	4%
Gujarat Fluorochemicals	47,370	59%	24%	22%	18%	11%
Jubilant Ingrevia	41,776	46%	24%	18%	7%	2%
Laxmi Organic Industries	29,854	36%	6%	6%	10%	1%
Navin Fluorine	23,494	57%	30%	27%	22%	8%
NOCIL	13,927	35%	4%	4%	5%	5%
Sudarshan Chemical Industries	33,456	41%	9%	8%	7%	1%
SRF	146,931	50%	17%	16%	8%	3%
Deepak Nitrite	82,819	16%	6%	6%	2%	0%
Vinati Organics	22,482	56%	22%	20%	24%	5%
Total	**603,012**	**45%**	**14%**	**13%**	**10%**	**5%**

Source: Anand Rathi Research, Geographic export mix includes analyst estimates; FY25 reflects the pre-tariff regime base

Performance vs Expectations: Variance Analysis

Fig 3 – Actual vs Consensus Estimates Deviation

(Rs m)	Q3FY26E (Estimates)		Rev			EBITDA			Deviation		Brief Reason
Security Name	Rev	EBITDA	Q3FY26	YoY	QoQ	Q3FY26	YoY	QoQ	Rev	EBITDA	
Acutaas Chemicals	3,556	1,114	3,932	43%	28%	1,507	119%	58%	11%	35%	Superior product mix, operating leverage benefits led by CDMO-driven scale-up in Advanced Intermediates.
Aarti Industries	20,863	2,893	23,190	26%	10%	3,220	39%	11%	11%	11%	Sharp volume recovery in MMA, NT and DCB; Energy application vol grew 78% y/y (up 13% q/q) in Q3.
Atul Ltd.	15,762	2,820	15,736	11%	1%	2,884	29%	8%	0%	2%	In-line operating performance on recovery in 2,4-D exports; Performance Chemicals margins remained soft
Balaji Amines	3,458	584	3,313	6%	-3%	567	24%	-5%	-4%	-3%	Balanced demand across amines, derivatives, and specialty chemicals
Chemplast Sanmar	11,625	563	8,351	-21%	-19%	-585	-282%	-235%	-28%	-204%	Suspension PVC impacted on weak demand, production & dumping issues; CMC impacted on Agro slowdown
Clean Science & Technology	2,364	861	2,197	-9%	-10%	725	-26%	-17%	-7%	-16%	Product mix pressure and lower contribution from top products weighed on profitability.
Deepak Nitrite	19,495	2,124	19,750	4%	4%	2,109	25%	3%	1%	-1%	Advanced intermediates weak on pricing pressure/global oversupply; Phenolics remained resilient.
Fine Organic Industries	5,258	1,113	5,548	8%	-7%	1,015	2%	-25%	6%	-9%	Subdued export volumes resulting in adverse operating leverage.
Gujarat Fluorochemicals	12,432	3,566	11,360	-1%	-6%	2,750	-6%	-24%	-9%	-23%	Weakness led by lower prices of R22, R125 and bulk chemicals
Galaxy Surfactants	13,012	1,078	13,295	28%	0%	1,194	13%	8%	2%	11%	Reformulation pressure, tariffs, GST correction - kept volumes flat; lower input costs lifted GM.
Jubilant Ingrevia	10,536	1,210	10,510	-1%	-6%	1,266	-8%	-7%	0%	5%	Pricing pressure across portfolio offsetting a healthy volume growth
Laxmi Organic	8,017	677	6,780	-14%	0%	130	-83%	-4%	-15%	-81%	Essentials stable; Specialties weakness on pricing and key-Agro product phase-out
Neogen Chemicals	2,163	330	2,200	9%	5%	320	-7%	7%	2%	-3%	Volume growth across base business led by toll manufacturing reliance amid Dahej plant rebuilding.
Navin Fluorine International	8,042	2,392	8,924	47%	18%	3,076	109%	25%	11%	29%	Specialty Chemicals grew on Nectar campaigns and pipeline deliveries; HPP/CDMO stayed flat.
NOCIL	3,248	257	3,158	-1%	-1%	268	12%	20%	-3%	4%	Drop in conversion cost led to healthy EBITDA improvement, despite gross spread dropping to a new low
PI Industries	17,688	4,726	13,757	-28%	-27%	3,023	-41%	-44%	-22%	-36%	CSM and Agrochem exports under pressure; domestic business faced volume/pricing decline.
Privi Specialty	6,504	1,503	6,046	23%	-11%	1,513	30%	-17%	-7%	1%	Sequential softness due to holidays in export markets and tariff impacting US
Rossari Biotech	5,749	731	5,817	13%	-1%	689	6%	-4%	1%	-6%	EBITDA impacted by EO constraints and higher operating cost towards new/existing facilities
SRF	38,076	8,228	37,125	6%	2%	7,800	26%	1%	-2%	-5%	Weakness in Specialty Chemicals, Performance Films & Foils offset by stronger Fluorochemicals (R-32).
Sudarshan Chemical	24,081	1,351	21,030	216%	-12%	379	-52%	-71%	-13%	-72%	Weak Europe and North America demand, higher-than-expected Heubach destocking impacted volumes.
Tatva Chintan Pharma Chem	1,314	246	1,313	53%	6%	255	259%	15%	0%	4%	PASC was the key growth driver on order fulfilments and scale-up, SDA and PTC saw mild softness
Tata Chemicals	38,770	5,370	35,500	-1%	-8%	3,450	-21%	-36%	-8%	-36%	Global soda ash oversupply and pricing pressure continued to hurt the US and overseas businesses
Vinati Organics	5,704	1,732	5,291	1%	-3%	1,608	13%	-10%	-7%	-7%	ATBS volumes up, but IBB/ antioxidants soft; higher fixed costs led by new ATBS capacity
Total	**2,77,716**	**45,468**	**2,64,124**	**10%**	**-4%**	**39,163**	**4%**	**-14%**	**-5%**	**-14%**	
Total (Ex-Sudarshan Chemical Industries) *	**2,53,635**	**44,117**	**2,43,094**	**4%**	**-3%**	**38,784**	**5%**	**-12%**	**-4%**	**-12%**	

*Source: Bloomberg, Anand Rathi Research, *Sudarshan Chemical Industries base quarter not comparable due to Heubach Acquisition.*

Valuation Summary

Fig 4 – Valuations – Indian companies

			Revenue	EBITDA	PAT	PE (x)			EV/EBITDA (x)			ROE (%)		
(Rs bn)	Rating	Mcap	FY25-28e	FY25-28e	FY25-28e	FY26e	FY27e	FY28e	FY26e	FY27e	FY28e	FY26e	FY27e	FY28e
Coverage														
Aarti Industries Ltd	Hold	163	16%	21%	35%	39.0	28.7	20.3	17.4	14.1	11.0	7.2	9.2	11.9
Atul Ltd	Buy	194	14%	17%	25%	29.3	23.7	20.7	16.4	13.4	11.4	11.2	12.5	12.9
Fine Organic Industries Ltd	Buy	139	16%	16%	12%	30.4	28.0	24.0	23.1	20.5	16.3	18.2	17.1	17.3
Galaxy Surfactants Ltd	Hold	68	12%	7%	7%	22.8	20.1	17.8	13.1	11.4	9.9	11.9	12.3	12.6
Jubilant Ingrevia Ltd	Buy	97	15%	22%	26%	34.1	25.4	19.0	18.2	14.2	11.3	9.3	11.6	14.0
NOCIL Ltd	Hold	25	9%	23%	22%	34.6	20.9	15.8	18.6	11.5	8.7	4.1	6.5	8.2
Rossari Biotech Ltd	Hold	28	12%	11%	9%	21.6	19.7	15.8	10.9	9.4	7.9	10.4	10.4	11.6
Sudarshan Chemical Industries Ltd	Buy	71	47%	40%	42%	235.2	28.7	15.2	16.5	9.9	6.7	0.9	7.0	12.2
Vinati Organics Ltd	Hold	156	16%	17%	15%	34.9	29.3	25.1	23.5	19.5	16.5	15.1	15.9	16.3
Non-Coverage														
Aether Industries Ltd	NR	130	33%	34%	30%	55.8	42.7	33.7	35.0	29.1	22.6	9.2	11.0	12.9
Alkyl Amines Chemicals	NR	77	12%	16%	16%	42.1	31.7	26.6	25.6	19.9	16.8	12.5	15.0	15.9
Balaji Amines Ltd	NR	35	9%	21%	13%	20.6	16.8	13.6	13.5	10.6	8.6	7.9	8.9	10.0
Clean Science & Technology Ltd	NR	76	17%	10%	11%	32.1	26.3	21.2	20.4	16.9	13.8	15.5	16.6	17.9
Deepak Nitrite Ltd	NR	220	7%	9%	7%	43.4	30.2	30.6	26.2	18.1	16.2	9.0	11.8	12.3
Gujarat Fluorochemicals Ltd	NR	375	17%	23%	31%	53.4	39.2	30.6	28.3	21.8	17.7	9.3	11.2	12.7
Laxmi Organic Industries Ltd	NR	38	12%	7%	12%	41.3	31.9	23.5	18.0	13.5	10.9	4.6	5.7	7.3
Navin Fluorine International Ltd	NR	333	26%	39%	47%	54.0	43.9	36.6	33.1	27.7	23.3	19.2	18.7	19.2
Neogen Chemicals Ltd	NR	36	42%	42%	51%	116.4	61.0	29.3	34.4	20.1	11.7	3.5	6.8	12.1
PI Industries Ltd	NR	463	4%	3%	2%	32.8	30.5	26.7	22.7	20.5	18.1	13.3	12.8	13.1
Privi Speciality Chemicals Ltd	NR	117	25%	21%	43%	37.8	30.7	22.2	19.9	16.3	12.3	22.6	22.3	24.1
SRF Ltd	NR	794	12%	20%	31%	43.0	34.7	28.3	23.9	20.1	16.9	13.8	15.1	16.0
Tatva Chintan Pharma Chem Pvt Ltd	NR	28	26%	72%	148%	63.3	41.6	32.5	30.0	20.8	16.5	5.9	8.3	9.7
Sector Average			**18%**	**20%**	**23%**	**50.2**	**30.7**	**23.7**	**21.8**	**17.1**	**13.7**	**10.9**	**12.3**	**13.8**

Source: Bloomberg, Anand Rathi Research Note: UR-Under Review, NR-Not Rated, Tatva excluded from sector average

Fig 5 – Valuations - Global companies

			Revenue	EBITDA	PAT	PE (x)			EV/EBITDA (x)			ROE (%)		
(Rs bn)	Curr	Mcap	FY25-28e	FY25-28e	FY25-28e	FY26e	FY27e	FY28e	FY26e	FY27e	FY28e	FY26e	FY27e	FY28e
Albemarle Corp	USD	19.8	6%	-231%	-206%	24.0	18.1	15.7	11.1	10.2	9.4	8.6	12.1	12.0
BASF SE	EUR	43.6	-2%	5%	29%	17.9	19.2	15.4	9.5	9.0	8.2	5.8	7.6	7.4
Celanese Corp	USD	5.9	0%	123%	-182%	11.2	8.7	7.1	9.0	8.4	8.0	10.8	12.6	13.8
Chemours Co/The	USD	2.6	5%	18%	79%	10.7	7.1	5.2	6.9	6.0	5.2	66.7	83.9	41.3
Clariant AG	CHF	2.6	0%	6%	7%	11.3	9.8	8.7	6.5	6.2	5.8	8.6	11.4	12.3
Croda International PLC	GBP	4.2	4%	9%	16%	21.1	18.9	16.8	12.1	11.0	10.1	7.6	9.0	10.2
Daicel Corp	JPY	434.8	3%	4%	1%	8.2	9.3	8.1	7.3	6.7	6.0	12.6	11.1	11.5
DSM-Firmenich AG	EUR	16.2	-4%	4%	60%	17.2	15.1	13.9	9.9	9.2	8.7	4.1	4.9	5.3
Eastman Chemical Co	USD	9.0	0%	-3%	-3%	13.6	11.8	10.4	8.8	8.2	7.8	11.3	12.7	13.8
Ecolab Inc	USD	86.1	6%	11%	12%	35.7	31.3	28.2	21.5	19.9	18.5	23.1	24.1	24.3
Glanbia PLC	EUR	4.0	3%	13%	30%	15.0	14.0	12.8	11.0	10.5	9.8	15.6	16.0	16.4
International Flavors & Fragrances Inc	USD	20.8	0%	-207%	76%	18.2	16.9	15.6	12.5	11.8	11.2	7.5	8.0	8.3
Kerry Group PLC	EUR	11.6	2%	8%	9%	14.3	13.0	11.7	10.8	10.1	9.4	11.9	12.4	12.6
Lonza Group AG	CHF	37.7	11%	24%	40%	29.7	24.7	21.6	17.4	15.2	13.4	12.8	14.3	15.0
Symrise AG	EUR	10.6	2%	4%	8%	21.1	18.8	17.2	12.0	11.6	10.9	11.5	12.8	13.1
Wanhua Chemical Group Co Ltd	CNY	266.0	10%	14%	14%	21.3	16.8	13.8	12.6	10.5	8.6	12.2	14.3	16.1
Zhejiang NHU Co Ltd	CNY	90.5	7%	4%	10%	13.8	13.4	12.0	9.4	9.2	8.5	20.2	18.1	17.2
Ex-India Average			**3%**	**9%**	**22%**	**17.9**	**15.9**	**14.0**	**11.1**	**10.2**	**9.4**	**16.0**	**18.0**	**15.5**
Global Average			**11%**	**14%**	**23%**	**34.1**	**23.3**	**18.8**	**16.5**	**13.6**	**11.5**	**13.4**	**15.2**	**14.6**

*Source: Bloomberg, Anand Rathi Research Note: * FY25/28E is equivalent to CY24/27E (global peers), Albemarle, Celanese and IFF excluded from sector average*

FY27/28 Earnings Estimate Changes

Fig 6 – Change in Consensus Estimates Post Q3FY26

Year	2027			2028		
Company	Revenue	EBITDA	PAT	Revenue	EBITDA	PAT
Alkyl Amines	-3.6%	-4.4%	-5.4%	-3.7%	-5.2%	-6.3%
Acutaas Chemicals	5.6%	13.4%	13.1%	8.5%	15.6%	16.6%
Aarti Industries	2.5%	0.9%	2.7%	2.2%	1.5%	3.0%
Atul Ltd	-2.1%	1.7%	0.9%	-1.5%	-1.7%	5.7%
Balaji Amines	0.0%	10.7%	0.0%	0.0%	12.0%	0.0%
Chemplast Sanmar	-6.8%	-19.9%	-75.4%	-5.0%	-7.7%	-21.9%
Clean Science and Technology	-12.7%	-17.2%	-17.9%	-11.3%	-16.2%	-18.0%
Deepak Nitrite	-3.3%	-7.0%	-9.1%	-1.9%	-5.1%	-7.5%
Fine Organic Industries	-0.9%	-3.1%	-3.7%	-2.8%	-4.9%	-5.4%
Gujarat Fluorochemicals	-8.7%	-9.1%	-11.8%	-7.8%	-7.9%	-10.2%
Galaxy Surfactants	1.8%	-0.7%	-1.1%	2.0%	-1.6%	-2.5%
Jubilant Ingrevia	-5.2%	-7.5%	-9.5%	-9.3%	-11.8%	-14.1%
Laxmi Organics	-3.4%	-15.7%	-24.1%	-2.4%	-14.9%	-20.7%
Neogen Chemicals	0.7%	-2.7%	3.6%	0.3%	0.0%	-2.2%
Navin Fluorine International	3.4%	10.1%	12.9%	3.7%	9.7%	12.4%
Nocil Ltd.	-2.2%	-7.4%	-7.0%	1.2%	-5.9%	-4.2%
PI Industries	-9.8%	-12.4%	-12.6%	-9.8%	-11.3%	-11.5%
Privi Specialty Chemicals	-4.5%	-3.3%	2.1%	-1.0%	-1.0%	0.4%
Rossari Biotech	-4.5%	-9.4%	-14.3%	-7.1%	-11.4%	-16.8%
Sudarshan Chemical Industries	-3.4%	-4.6%	-6.5%	-3.3%	-5.8%	-8.9%
SRF	-3.1%	-3.1%	-4.3%	-2.8%	-3.0%	-4.1%
Tatva Chintan Pharma Chem	-0.4%	-2.1%	-6.6%	-0.6%	3.5%	-2.0%
Tata Chemicals	-2.8%	-10.7%	-25.5%	-1.8%	-8.2%	-34.9%
Vinati Organics	-5.2%	-4.3%	-3.5%	-5.1%	-5.5%	-3.4%

Source: Bloomberg, Anand Rathi Research

Fig 7 – Chemical Sector Valuations (1 yr fwd)



Source: Bloomberg, Anand Rathi Research, 23 leading companies included

Q3FY26 Earnings Trends

Fig 8 – Revenue grows 14% y/y, 2% q/q aided by volume



Source: Companies, Anand Rathi Research

Fig 9 – Gross margin at cyclical low on pricing pressure



Source: Companies, Anand Rathi Research

Fig 10 – Cost savings help contain opex (+3% y/y / +1% q/q)



Source: Companies, Anand Rathi Research

Fig 11 – EBITDA margin improves on operating leverage



Source: Companies, Anand Rathi Research

Fig 12 – Depreciation (up 10% y/y & 2% q/q), intensity wanes



Source: Companies, Anand Rathi Research

Fig 13 – Finance costs soften (down 14% y/y & 16% q/q)



Source: Companies, Anand Rathi Research

Fig 14 – PAT (up 34% y/y & 3% q/q) on lower finance cost and ETR



Source: Companies, Anand Rathi Research

Note - Aggregates include Coverage Universe, SRF, NFIL

Q3FY26 Performance Overview

Coverage companies

Fig 15 – Aarti Industries

(Rs m)	Q3FY26	y/y (%)	q/q (%)
Revenue	23,190	26.0	10.4
EBITDA	3,220	39.4	10.7
EBITDA Margin (%)	13.9	133 bps	3 bps
APAT	1,509	228.0	79.6
EPS (Rs)	4.2	228.0	79.6

Comments: Reported a strong performance in Q3FY26, with EBITDA rising by 39% y/y and 11% q/q to Rs3.2bn. EBITDA margin rose 133bps y/y (flat q/q) to 13.9%, driven by a sharp recovery in volume in MMA, NT and DCB. APAT stood at Rs1.5bn (up 228% y/y and 80% q/q), after adjusting for exceptional charge of Rs150mn (for Labour Code). Strong gasoline-naphtha spreads boosted MMA output (~69kt, 96% utilisation), while DCB volume rose on robust PDCB demand. Non-energy segments remained mixed, while agro and dyes saw volume recovery (amid Chinese price pressure), PDA chain remained subdued, and higher exports increased WC sequentially.

Source: Company, Anand Rathi Research

Fig 16 – Atul Ltd.

(Rs m)	Q3FY26	y/y (%)	q/q (%)
Revenue	15,736	11.1	1.4
EBITDA	2,884	28.7	7.8
EBITDA Margin (%)	18.3	251 bps	109 bps
APAT	1,939	60.9	8.2
EPS (Rs)	65.9	60.9	8.2

Comments: Adj. EBITDA stood at Rs2.9bn, post labour law provision adjustment, aided by stability in Life Sciences Chemicals Revenue at Rs4.5bn (up 9% y/y and 3% q/q) on better product-mix and spread improvements in 2-4, despite tariff headwinds leading to stable margin. Flat revenue in Performance Chemicals at Rs115.5bn (up 11% y/y and flat q/q) was likely on seasonal slowdown in offtakes, thus, impacting margin on q/q comparison. APAT came in at Rs1.9bn (up 61% y/y and 8% q/q) on higher other income (up 145% y/y; down 20% q/q), lower finance cost and (up 14%y/y; down 24% q/q) lower ETR (19.8%).

Source: Company, Anand Rathi Research

Fig 17 – Fine Organic Industries

(Rs m)	Q3FY26	y/y (%)	q/q (%)
Revenue	5,548	8.1	-7.1
EBITDA	1,015	2.4	-24.9
EBITDA Margin (%)	18.3	-102 bps	-434 bps
APAT	792	-4.4	-27.1
EPS (Rs)	25.8	-4.4	-27.1

Comments: Stable demand with subdued export volume led to revenue of Rs5.5bn (up 8 y/y and down 7% q/q). Slight rise in RM prices led to 139bps y/y and 353bps q/q contraction in gross margin. Adj. EBITDA stood at Rs1bn (up 2% y/y; and down 25% q/q) post adjustment for labour code impact and margin came in at 18.3%, impacted by lower gross margin and muted volume due to seasonality and maintenance shutdown, resulting in adverse operating leverage. APAT at Rs792m (down 4% y/y and 27 q/q) due to lower operating profit and other income.

Source: Company, Anand Rathi Research

Fig 18 – Galaxy Surfactants

(Rs m)	Q3FY26	y/y (%)	q/q (%)
Revenue	13,295	27.6	0.3
EBITDA	1,194	13.1	8.0
EBITDA Margin (%)	9.0	-116 bps	64 bps
APAT	686	6.1	3.1
EPS (Rs)	19.3	6.1	3.1

Comments: Revenue came in at Rs13.2bn (up 28% y/y and flat q/q) led by flat y/y and q/q volume, pressured by US tariffs, GST-led inventory correction in India and client reformulation. EBITDA rose 13% y/y (up 8% q/q) to Rs1.2bn, aided by gross margin gains on 8% q/q fall in input cost leading to 40bps rise in gross margin and supporting EBITDA margin at 9% (down 116bps y/y and 64bps q/q). APAT, adjusted for Rs119m provision towards new Labour Code, grew by 6% y/y and 3% q/q to Rs686m.

Source: Company, Anand Rathi Research

Fig 19 – Jubilant Ingrevia

(Rs m)	Q3FY26	y/y (%)	q/q (%)
Revenue	10,510	-0.5	-6.2
EBITDA	1,266	-8.5	-6.6
EBITDA Margin (%)	12.0	-105 bps	-5 bps
APAT	563	-18.9	-19.0
EPS (Rs)	3.6	-18.9	-19.0

Comments: Revenue stood at Rs10.5bn (flat y/y and down 6% q/q) on subdued pricing, with SC and CI down 2% y/y each, while NHS grew 6% y/y on strong volume. Margin was stable in SC (25.4%) aided by Fine Chemicals, softer in NHS (11%) on B3/Choline correction and steady in CI. Higher depreciation (up 13% y/y and 9% q/q) dragged APAT by 19% y/y/q/q (adjusted for Rs130mn exceptional loss). The management sees pricing bottoming with early recovery in Pyridine, B3 and Acetic Acid. Large agro-innovator CDMO project (minimum offtake, >20% EBITDA margin) remains on track for Mar-26 dispatches.

Source: Company, Anand Rathi Research

Fig 20 – NOCIL

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	3,158	-0.7	-1.5	Revenue came in at Rs3.16 bn (flat y/y and q/q), with strong domestic volume growth being offset by lower export volume due to seasonal effects and reduced orders from the US market on tariff uncertainties, coupled with lower realisations due to competitive pressure. EBITDA rose to Rs268m, with margin rising 94bps y/y and 153bps q/q to 8.5%, aided by lower conversion cost. APAT increased 1% y/y and 7% q/q to Rs130m, with lower other income largely offset by reduced tax outgo and adjustments related to New Labour Code.
EBITDA	268	11.6	20.2	
EBITDA Margin (%)	8.5	94 bps	153 bps	
APAT	130	0.5	7.0	
EPS (Rs)	0.8	0.5	7.0	

Source: Company, Anand Rathi Research

Fig 21 – Rossari Biotech

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	5,817	13.4	-0.8	Revenue grew by 13% y/y with ~10-12% volume-led growth. Exports accounted for 33% of Q3 sales and up 26% in 9M. EBITDA margin fell to 3.5-year low of 11.8% (with core B2B at ~14% vs. normalised 15-16%.) due to pricing pressure, EO constraints and higher operating cost from new/existing facilities. HPPC remained subdued (up 10% y/y and down 6% q/q). Institutional Cleaning / B2C fell 15% y/y and 9% q/q, intensifying concerns given its already loss-making profile. TSC and AHN delivered strong growth stabilising consolidated revenue, driven by higher exports. APAT impacted 11% q/q, led by higher depreciation and interest cost.
EBITDA	689	6.3	-4.2	
EBITDA Margin (%)	11.8	-79 bps	-43 bps	
APAT	328	3.4	-11.1	
EPS (Rs)	5.9	3.3	-11.1	

Source: Company, Anand Rathi Research

Fig 22 – Sudarshan Chemical Industries

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	21,030	215.6	-11.9	Delivered a weak Q3FY26, led by weaker demand (especially in Europe & North America) and higher-than-expected customer inventory destocking especially in acquired (Heubach) portfolio. Revenue fell 12% q/q (y/y not comparable) to Rs21bn, with Heubach/Legacy business contributing Rs14.8/6bn (down 12% q/q and 8% q/q). Adj. EBITDA plummeted to Rs409m, with Heubach at Rs380m loss (margin at -2.6% vs. 1.5% in Q2) and Legacy pigment business at Rs815m (+3%y/y; 13.7% margin). Demand recovery is expected from Q4FY26, as destocking slows and global orders normalise (improvement already visible in Jan-Feb'26). EBITDA is expected to remain compressed over the next 3 quarters on €30-40m inventory reduction in Heubach.
EBITDA	379	-52.0	-71.3	
EBITDA Margin (%)	1.8	-1005 bps	-374 bps	
APAT	(730)	-332.9	-478.2	
EPS (Rs)	-9.3	-305.2	-478.2	

Source: Company, Anand Rathi Research

Fig 23 – Vinati Organics

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	5,291	1.4	-3.1	Revenue stood at ~Rs5.3bn (down 3% q/q), supported by volume uptick in ATBS portfolio offset by pressure in IBB and antioxidants. EBITDA came in at Rs1.6bn (up 13% y/y and down 10% q/q) below expectations on higher fixed costs of additional ATBS capacity commenced in Nov-25. APAT at ~Rs1.1bn (up 14% y/y and down 16% q/q) on higher depreciation and sequentially lower other income.
EBITDA	1,608	12.6	-10.0	
EBITDA Margin (%)	30.4	302 bps	-230 bps	
APAT	1,085	13.5	-15.9	
EPS (Rs)	10.5	13.5	-15.9	

Source: Company, Anand Rathi Research

Broader sector performance

Fig 24 – Acutaas Chemicals

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	3,932	43.0	28.4	Revenue grew by 43% with record profitability, led by 76% gross profit growth and >2x EBITDA y/y on the back of a superior product-mix and strong operating leverage. Advanced Intermediates was the primary engine delivering 47% y/y growth, with CDMO-driven scale-up and disciplined margin-focused API growth. Specialty chemicals saw early recovery (Baba Fine Chemicals), while cost efficiency, especially energy savings from solar, further boosted margin.
EBITDA	1,507	119.4	58.0	
EBITDA Margin (%)	38.3	1335 bps	719 bps	
APAT	1,062	134.5	47.8	
EPS (Rs)	13.2	19.2	49.5	

Source: Company, Anand Rathi Research

Fig 25 – Anupam Rasayan

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	5,124	31.3	-29.9	Reported revenue grew 31% y/y but down 30% q/q to Rs5bn, aided by scale-up of commercial molecules, higher asset utilisation and strong execution with significant contribution from LoIs/contracts. Pharma (up 85% y/y) and Performance Materials (up 245% y/y), Japan traction (~17% revenue this quarter). Performance was sequentially weak on stronger base effect. EBITDA stood at Rs1.3bn (up 3% y/y and down 6% q/q) with q/q margin recovery to 25%. Export contribution remained strong at 58% of revenue, reflecting a diversified global customer base.
EBITDA	1,275	2.6	-6.1	
EBITDA Margin (%)	24.9	-698 bps	631 bps	
APAT	606	114.9	36.5	
EPS (Rs)	4.31	67.9	9.7	

Source: Company, Anand Rathi Research

Fig 26 – Chemplast Sanmar

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	8,351	-21.0	-19.2	Revenue stood at Rs8.4bn (up 21% y/y and down 19% q/q) on weak suspension PVC (hit by seasonal softness, feedstock issues, and continued dumping) and agro slowdown-led margin pressure in CMC causing Rs1.2bn net loss. The management expects PVC recovery ahead (domestic price hikes + China's export rebate withdrawal from Apr-26), while Specialty Chemicals delivered 13%y/y volume growth and is progressing on MPB 3/4 and the R-32 project. Value-added chemicals were impacted by global pricing and Mettur issues but should normalize by Mar-26.
EBITDA	-585	-282.4	-235.3	
EBITDA Margin (%)	-7.0	-1003 bps	-1119 bps	
APAT	-1,209	147.8	136.8	
EPS (Rs)	-7.5	141.3	132.3	

Source: Company, Anand Rathi Research

Fig 27 – Clean Science Technology

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	2,197	-8.8	-10.2	Revenue declined 10% q/q and 9% y/y, led by volume softness across regions. Demand weakness persisted in US/EU, order postponements in India, and continued pressure in Agchem. Product mix pressure and lower contribution from top products (75% in Q3 vs. 80% q/q) weighed on profitability. Adj. EBITDA margin fell to 33% (down 791bps y/y and 262bps q/q), as MEHQ volume was impacted on industry-wide pricing pressure. BHA was affected by tariffs, while 4-MAP saw permanent customer loss. HALs outperformed with 55% y/y growth with volume rising to 810-tonne. Thus, APAT fell to ~Rs0.5bn (down 30% y/y and 17% q/q) despite higher other income.
EBITDA	725	-26.4	-16.8	
EBITDA Margin (%)	33.0	-791 bps	-262 bps	
APAT	461	-30.1	-17.2	
EPS (Rs)	4.32	-30.1	-17.2	

Source: Company, Anand Rathi Research

Fig 28 – Deepak Nitrite

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	19,750	3.8	3.8	Revenue stood at Rs19.7 bn (up 4% y/y and q/q), driven by higher phenolics volume. EBITDA rose to Rs2.1bn with 11% margins, though advanced intermediates stayed weak due to pricing pressure and global oversupply. Phenolics margin remained relatively resilient. APAT stood at Rs1bn, affected by exceptional labour-code provisioning. Near-term outlook remains mixed amid Chinese oversupply and soft global spreads.
EBITDA	2,109	25.1	3.2	
EBITDA Margin (%)	10.7	182 bps	-6 bps	
APAT	1,091	11.2	-8.1	
EPS (Rs)	8	11.2	-8.1	

Source: Company, Anand Rathi Research

Fig 29 – Epigral Ltd

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	5,971	-7.5	1.7	Revenue stood at Rs6bn (down 8% y/y and up 2% q/q), driven by mix-led gains rather than volume, while EBITDA fell to Rs1 bn (down 43% y/y and 22% q/q; 17% margin) on weaker realisation, higher RM cost and high-cost PVC/CPVC inventory. Derivatives and specialty contribution improved to ~52% of revenue, though utilisation remained soft at ~78%, with CPVC the main drag due to sharp PVC price correction and weak monsoon demand.
EBITDA	1,027	-43.7	-22.4	
EBITDA Margin (%)	17.2	-1108 bps	-533 bps	
APAT	391	-62.3	-23.6	
EPS (Rs)	9.07	-62.6	-23.6	

Source: Company, Anand Rathi Research

Fig 30 – GHCL

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	7,565	-2.8	4.9	Revenue stood at Rs7.5bn (down 3% y/y and up 5% q/q) due to weak domestic realisation and a planned shutdown. Sales volume grew ~5-7% y/y, offsetting a 20ktpa shutdown impact. EBITDA dropped to Rs1.5bn (down 31% y/y) with margin compressing to 21% on continued pricing pressure, leading to an APAT at Rs1.1bn (down 37% y/y). The Kutch greenfield soda ash project is progressing slower than expected (FY30). With no ADD and MIP expiry, oversupply from low-priced imports is expected to keep soda ash prices subdued near-term.
EBITDA	1,587	-31.0	0.9	
EBITDA Margin (%)	21.0	-857 bps	-83 bps	
APAT	1,060	-37.1	-0.6	
EPS (Rs)	11.3	-36.4	0.9	

Source: Company, Anand Rathi Research

Fig 31 – Gujarat Fluorochemicals

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	11,360	-1.0	-6.1	Revenue stood at Rs11.3bn (flat y/y and down 6% q/q) impacted by weak R-22/R-125 pricing and delayed R-32 start-up, partially offset by steady fluoropolymer growth. Weakness was led by lower realisation, tariff-led pressure in exports and seasonal slowdown across global markets. EBITDA came in at Rs2.7 bn (down 6% y/y and 24% q/q), with margin at 24% (down 140 bps y/y and 587bps q/q). APAT declined to Rs900m (down 29% y/y and 50% q/q) with an exceptional charge Rs130m related to labour code adjustments. R32 ramp-up is delayed to FY27. LiPF6 supplies commenced in Dec-25 and other products (binders, cathode materials) under qualification.
EBITDA	2,750	-6.5	-24.5	
EBITDA Margin (%)	24.2	-140 bps	-587 bps	
APAT	899	-28.0	-49.8	
EPS (Rs)	8.2	-28.0	-49.8	

Source: Company, Anand Rathi Research

Fig 32 – Laxmi Organic Industries

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	6,780	-13.8	0.2	Revenue fell by 14% y/y (flay q/q) to Rs6.8bn post adjustment for one-time impact of liability reversal. Adj. EBITDA plunged 83% to Rs130m, with margin at 1.9%. Essentials saw stable volume despite ETAC pricing drag, while Specialties fell 30% y/y on price moderation, a one-time base effect, and an Agro product phase-out, with margin remaining suppressed by feedstock softness and cost absorption. It reported Adj. Loss of Rs109m on account of lower other income, higher interest costs and adjustment for liability reversal, labour reform provisioning.
Adj. EBITDA	130	-82.6	-4.6	
Adj. EBITDA Margin (%)	1.9	-759 bps	-10 bps	
APAT	(109)	-137.3	93.7	
EPS (Rs)	-0.4	-137.3	93.7	

Source: Company, Anand Rathi Research

Fig 33 – Navin Fluorine International

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	8,924	47.2	17.7	Strong performance with revenue of Rs8.9bn (up 47% y/y and 18% q/q), led by volume growth in Specialty Chemicals on the back of Nectar and other deliveries in pipeline. HPP and CDMO remained sequentially flat. EBITDA margin reached 34.5%, driven by Specialty Chemicals and CDMO yielding operating leverage. APAT stood at Rs2bn (up 141% y/y and 36% q/q) adjusted for labour code provisioning, owing to improved operating profitability.
EBITDA	3,076	108.8	24.9	
EBITDA Margin (%)	34.5	1017 bps	201 bps	
APAT	2,013	140.8	35.7	
EPS (Rs)	39.3	140.8	35.7	

Source: Company, Anand Rathi Research

Fig 34 – Neogen Chemicals

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	2,200	9.2	5.4	Revenue stood at Rs2.2bn (up 9% y/y and 5% q/q), aided by volume growth across base chemicals, partly offset by disruption from Dahej fire and continued reliance on toll manufacturing. EBITDA stood at Rs320m (down 8% y/y and up 7% q/q) with EBITDA margin at 14.5% (down 265bps y/y and up 20bps q/q). APAT declined sharply to Rs38m (down 62% y/y and up 14% q/q) impacted by higher tolling cost, reconstruction expenses, and elevated insurance and finance cost and due to higher interest cost and operating inefficiency post-fire. Dahej recommissioning is expected in Q1FY27 and battery chemicals ramp-up intact. Near-term profitability is expected to remain subdued until plant normalisation.
EBITDA	320	-7.6	6.8	
EBITDA Margin (%)	14.5	-265 bps	+19 bps	
PAT	38	-61.8	13.6	
EPS (Rs)	1.4	-61.8	13.6	

Source: Company, Anand Rathi Research

Fig 35 – SRF

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	37,125	6.3	2.0	Mixed performance with revenue at Rs37bn (up 6% y/y and 2% q/q) and EBITDA at Rs7.8bn (up 26% y/y and 0.8% q/q). Chemicals segment anchored by Fluorochemicals remained the standout, with EBIT rising 36% y/y and margin expanding to 27.2%, though slightly softer q/q (down 169 bps), while Performance Films & Foils weakened q/q with EBIT down 20% and margin contracting by 139bps. Technical Textiles faced margin pressure. Profitability remined strong with PBT rising by 42% y/y and 2% q/q, while PAT was impacted by labour-code adjustments.
EBITDA	7,800	25.9	0.8	
EBITDA Margin (%)	21.0	326 bps	-26 bps	
APAT	4,876	79.9	25.6	
EPS (Rs)	16.4	79.9	25.6	

Source: Company, Anand Rathi Research

Fig 36 – Tata Chemicals

(Rs m)	Q3FY26	y/y (%)	q/q (%)	Comments
Revenue	35,500	-1.1	-8.4	Revenue stood at Rs35bn (broadly flat y/y and down 8% q/q), while EBITDA dropped to Rs3.5bn (down 21% y/y and 36% q/q) with margin falling to 9.7% (down 237bps y/y and 413bps q/q) on persistent pricing pressure. Domestic prices remain weak amid continued low-cost imports, though higher volume provided partial support. APAT missed estimates due to Rs540m exceptional loss. With no ADD imposition and MIP expiry in Dec-25, oversupply from cheap imports is expected to keep soda ash prices subdued in the near-term.
EBITDA	3,450	-20.5	-35.8	
EBITDA Margin (%)	9.7	-237 bps	-413 bps	
APAT	-390	NA	NA	
EPS (Rs)	-1.53	NA	NA	

Source: Company, Anand Rathi Research

Management commentary

Fig 37 – Key highlights from management commentary across domestic companies

Company	Outlook
Aarti Industries	FY26 capex is guided at ~Rs11bn (vs. Rs10bn earlier) with Zone 4 total at Rs16-18bn; FY27 capex to be significantly lower. MMA capacity will rise from ~290kt to ~360kt by Q4FY26. In the near-term, US tariff reduction (from 50%+ to 18%) should support realisation and volume across MMA, DCB and PDA. In the medium-term, the management targets MMA at 30-40% of portfolio and expects anti-involution and EU/US trade deals to aid margin recovery. Key drivers include Zone 4 ramp-up, DCB debottlenecking (120 to 140ktpa) and JV revenue of Rs3-4bn.
Acutaas Chemicals	The management raised FY26 revenue growth guidance to ~30% (from 25%) and upgraded EBITDA margin guidance to 32-35% (from 28-30% earlier), backed by a strong OB. CDMO is targeting Rs10bn revenue by FY28, with four products validated and meaningful contribution expected from FY27. Battery chemicals (VC/FEC, 4ktons total capacity) is expected to begin commercialisation by Q1FY27 with confirmed FY27 orders; Phase-II capex (~Rs400m) to be completed by Q1FY27. FY26 capex is ~Rs2.2bn plus ~Rs1.3bn Indichem investment. Semiconductor JV revenue is expected from CY27 with asset turns ~1x and margins above pharma.
Anupam Rasayan	LoIs/contracts contributed >Rs2.5bn in 9MFY26, exports accounted for 58% of revenue. WC stood at ~250 days, which it aims to reduce to 220-200 in the near-term and ~180 by FY27. The management expects growth momentum into next year, aided by OB execution and Jayhawk acquisition (EPS-accretive).
Chemplast Sanmar	The management expects suspension PVC to reach PBT breakeven in Feb-Mar aided by Rs7-8/kg price hike and rollback of discounts, with Chinese export rebate withdrawal (13% or US$70-80/MT) effective Apr-26 seen as structurally positive. Paste PVC prices were raised Rs2,000/MT with demand up 8% y/y in 9M and facility at full utilisation. CMCD's Rs10bn revenue target is deferred by a few quarters but guided for FY27-28 with 20-25% steady-state margin. R-32 capacity (14ktpa) targets ~11ktpa in first full year with Rs5.5-6bn revenue. Caustic prices seen range-bound at Rs30,000-34,000/MT.
Clean Science & Technology	The management indicated current pricing stress may persist for 1-2 quarters. HALS volume grew 6% q/q to ~810 tonne (9M: 2k tonne; up 55% y/y), targeting ~50% utilisation over two years. Hydroquinone/catechol plant commissioned in Dec-25. ~15% captive HQ use, balance external sales; Performance Chemicals 2 are likely to commercialise in Q1FY27. HQ margin is expected between HALS and parent levels.
Deepak Nitrite	Nitric acid plant was commissioned mid-Dec'25. The company expects near-100% internal consumption from Q4, normalising AI margin after spot purchases compressed Q3 profitability. The management expects Q4 to improve sequentially and Q1FY27 to be better, aided by ADD removal on US sodium nitrite exports (earlier ~5ktpa under ~105% tariff overhang). Integration across ammonia-to-amines, MIBK/MIBC commissioning in Q4, fluorination ramp-up in Q1FY27, ~15 new products in pipeline and polycarbonate commissioning targeted in the medium term (by Dec-27).
Epigral	The management expects Q4 margin to improve to ~21-23%, as PVC prices recover and high-cost inventory impact fades. CPVC demand is ~280ktpa in FY26, guided to grow 10-12% annually, reaching ~500ktpa by FY30; capacity expansion (commissioning Sep-26) may see 6-12 months of lower utilisation before normalisation. Chlorotoluene volume is ramping with meaningful P&L contribution from FY27. ECH realisation stood at Rs170/kg, aided by higher glycerin cost. Net debt/EBITDA is 1x, providing capex headroom.
Galaxy Surfactants	Reformulation capability ready with volume to pick up from Q4, supporting a gradual recovery in India and AMET as supplies normalise. A key client in India and improving US demand on trade deal are expected to drive volume through FY27, while RM softness is unlikely to affect profitability due to pricing discipline. Early traction is visible in Q4FY26, with deeper Tier II–III customer engagement planned to offset Tier-I volatility.
GHCL	The management expects India Soda Ash demand growth of ~5% in FY26 and ~5.5-6% in FY27, led by solar glass demand rising from ~11k tonne/month to ~28k tonne by Mar-27. Bromine (2,800tpa) and Vacuum Salt commissioning is targeted by Q4FY26, with higher margin but limited revenue contribution. Greenfield soda ash remains land-delayed, with potential commissioning by 2030. Key risks include elevated imports, lack of ADD and global oversupply.
Gujarat Fluorochemicals	The management expects refrigerant profitability to improve as the US tariffs reduce from 50% to 18% and R-32 ramps up; Phase-I capacity targets 20ktpa with longer-term intent up to ~30ktpa by Dec-27. Fluoropolymers grew 14% y/y, with strong semicon-led PFA demand and continued elastomer share gains; near-term softness stemmed from tariff uncertainty and inventory destocking. Battery materials see commercial LiPF6 supplies (formula-linked pricing), binder revenues from H2FY27, and CAM ramp post-qualification, with current capacities targeted for full utilisation by FY28.

Source: Company, Anand Rathi Research

Key highlights from management commentary across domestic companies

Company	Outlook
Jubilant Ingrevia	FY26 EBITDA is expected to exceed the 8% 9M growth rate, with a stated multiyear aspiration of ~20% EBITDA CAGR. Pricing across pyridine and vitamin B3 has bottomed with recent 7-8% B3 price uptick and acetic acid recovery; Q4 is expected to improve sequentially. The agro CDMO plant will commence dispatches by Mar-26, operating at >20% EBITDA margin with full-potential ramp from start (Q1FY27). Confirmed CDMO wins now total 16 molecules (~Rs 14bn peak over 3-4 years).
Laxmi Organic Industries	Acetic acid rebounded from US$320-330 to US$360-380, with ethyl acetate spreads improving from US$90-100 to ~US$130; near-term pricing expected above US$340. Dahej Phase-II (of Rs7.1bn capex; ~65% specialties) completes by Q4; FY27 expected to see qualification-led ramp-up, stronger in FY28. Fluoro intermediates revenue target of Rs700-800m in FY26 remains on track.
Navin Fluorine	The management guided for sustainable annual EBITDA margin of ~30% +/- 200bps rather than quarterly peaks. R-32 utilisation remained at 100%, while incremental 15ktpa R-32 capacity is on track for Q3FY27 commissioning. cGMP-4 Phase-1 has commenced commercial supplies with full utilisation expected in FY27, supporting three-year visibility. In the near-term, all three verticals show sequential growth momentum with improved realisation in HPP and CDMO. In the medium-term, Wave-2 capex including MPP debottlenecking and Chemours project (Q1FY27 completion) underpin growth, alongside advanced materials and electronic-grade fluorochemicals optionality.
Neogen Chemicals	The management reiterated FY27 battery chemicals revenue of Rs4-5bn, assuming Dahej approvals by Jun-26 and electrolyte sales from Q2, while Pakhajan salt sales in Q4 are kept as backup. Pakhajan commissioning by H1/H2 FY27 for electrolyte/salts, with 30ktpa electrolyte capacity and 5.5ktpa salt capacity; salt utilisation is targeted at ~80%. Base business is expected to deliver double-digit growth in FY27.
NOCIL	Volume growth guided at 3-4% despite flat 9M. Domestic volume grew by high single digit and strong double-digit y/y, while exports fell 8-9% in 9MFY26 due to US tariffs; lost US volume (~50%) are expected to recover within 2-3 months. FY27 export growth is guided in double-digit, aided by tariff normalisation and India-EU FTA (from CY27). TDQ capacity (20% expansion) will start trials in H1CY26, with gradual ramp-up from FY27; new products can add 10-12% to current volume over time. The management targets ~150bps annual margin improvement over 2-4 years.
Rossari Biotech	The management guides consolidated margin at 12-13% over the next year, with B2B at ~15%, pending EO supply normalisation by Q3FY27; optimal utilisation of 15ktpa ethoxylation plant (10-15% currently) is targeted over 2 years, reaching ~90% by FY27-end. FY26 capitalisation is ~Rs 2 bn; major capacity capex is complete. KSA greenfield is under evaluation (initial US$8m equity approval; capex higher). Key drivers include bio-surfactants (~300 tonnes FY27), premix plant, export expansion; key monitorable are EO availability, muted domestic textile demand and B2C drag.
SRF	The management maintained FY26 capex guidance of Rs22-23bn and indicated first-phase Odisha investment for next-generation gases at Rs15-20bn in FY27. Q4 is expected to be significantly better on pent-up agro POs. Pharma is ~10% of specialty, targeted to reach at least 20%, aided by a second plant (Rs1.8bn, commissioning in ~8 months). HFC capacities are fully utilised; growth hinges on quota maximisation and firm global prices.
Sudarshan Chemical Industries	The management expects Q4 business EBITDA at €9-10m vs. €6.5m run-rate, supported by customer restocking from Jan-26 and value capture of Rs400m realised so far. Over the next three quarters, inventory will be reduced by €30-40m, temporarily lowering reported EBITDA by €9-12m due to overhead absorption but improving cash flows and net debt. Long term, synergy-led cost optimisation and gradual ramp-up target €90-100m EBITDA on normalised demand, with fixed-cost reduction and portfolio synergy as key drivers; risks include demand volatility and high fixed-cost sensitivity.
Tata Chemicals	The management indicated soda ash demand remains flat in the near-term amid oversupply, with pricing expected to stay at current subdued levels given elevated inventories. US domestic realisations are down ~US$5/tonne y/y, while exports to Southeast Asia are being curtailed below US$155-160/tonne, implying temporary volume moderation. UK turnaround remains ~6 months behind; earlier guidance of Rs2.5 bn FY26 EBITDA and Rs600-650m quarterly run-rate is now deferred, though break-even is targeted in Q4 and profitability next year. Capex remains India-focused: Rs5.2bn iodised salt (210ktpa), Rs7.8bn silica (50ktpa), Rs1.4bn dense ash (350ktpa), all targeting >16-18% returns.

Source: Company, Anand Rathi Research

Global Chemicals – Outlook

Fig 38 – Albemarle Corporation

($m)	CY25	CY24	y/y (%)
Revenue	5,143	5,377	-4.4
Adj EBITDA	1,098	1,140	-3.7
Adj EBITDA Margin (%)	21.3%	21.2%	15 bps
Net Income	-267.00	-1,179.0	-NA
Adj EPS ($/ sh)	-0.79	-2.34	NA

Comments/ Outlook

Delivered solid CY25 with 7% volume growth and strong cost discipline, driving $1.3bn OCF and $692m FCF despite softer lithium pricing. Lithium demand expected at 25% y/y in 2026, driven by energy storage systems. For FY26, Energy Storage expects flat volume but stronger EBITDA, supported by accretive impact of idling Kemerton Train 1 and underpinned by ~40% of salts volume sold via long-term, index-linked contracts with price floors. Specialties to face margin normalisation and softer early-year volume due to JBC flooding impact, while Ketjen's contribution becomes immaterial post-divestiture in Q12026.

Source: Company, Anand Rathi Research (Reported Non-GAAP numbers)

Fig 39 – Celanese Corp.

($m)	CY25	CY24	y/y (%)
Revenue	9,544	10,268	-7.1
Op. Profit	-786	-720	NA
Op. profit Margin (%)	-8.0	-7.0	
PAT	-1151	-1534	NA
EPS($/ sh)	-10	-14	NA

Comments/ Outlook

Faced lower-than normal demand levels in key end-markets like automotive, paints, coatings, and construction, with volume and pricing decline. Strong cost actions supported $773m in FCF despite an operating loss driven by goodwill impairment. For CY26, Celanese expects another strong free cash-generation year ($650-750m) supported by continued cost reduction, footprint optimisation, and pipeline improvements, even as end-market demand remains muted. Engineered Materials is positioned for mix enrichment and cost-driven margin support, with Q1 EBIT guided at $210-230m despite ongoing volume softness. Acetyl Chain is set for lower early-2026 earnings due to acetate tow dividend timing and methanol maintenance, with Q1 EBIT of $110-125m aided by productivity and footprint actions amid persistent vinyls and tow weakness.

Source: Company, Anand Rathi Research (Reported GAAP numbers)

Fig 40 – Corteva

($m)	CY25	CY24	y/y (%)
Revenue	17,401	16,908	2.9
Adj. EBITDA	3,849	3,376	14.0
Adj. EBITDA Margin (%)	22.9%	20.0%	294 bps
Adj. EPS ($/ sh)	3.3	2.6	30.2

Comments/ Outlook

For 2026, Corteva expects low- to mid-single-digit revenue growth and EBITDA of $4-4.2bn (vs. $3.8bn in 2025), driven by Crop Protection volume gains in new products/biologicals, seed growth from mix and licensing, and productivity benefits partly offset by tariffs. Bayer litigation resolution provides long-term clarity on technology access, licensing and regulatory certainty, accelerates royalty neutrality to 2026, and positions the company for a projected $1bn net royalty benefit by 2035, as it transitions toward a net-licensor model.

Source: Company, Anand Rathi Research (Reported GAAP numbers, adj. are Non-GAAP)

Fig 41 – Chemours

($m)	CY25	CY24	y/y (%)
Revenue	5,808	5,782	0.4
Adj. EBITDA	742	768	-3.4
Adj. EBITDA Margin (%)	12.8	13.3	-51 bps
Adj. EPS ($/ sh)	0.95	1.19	-20.2

Comments/ Outlook

The company delivered $5.8bn sales and $742m CY25 Adj. EBITDA, driven by 56% y/y Opteon growth and strong TSS results. For 2026, guidance calls for 3–5% sales growth, $800-900m Adj. EBITDA, $275-325m capex, and >25% FCF conversion. Growth will be led by TSS with 30-40% higher Opteon sales in Q1, as AIM Act regulations accelerate low-GWP adoption. Favorable mix, aftermarket demand and cost actions support margins. In contrast, TT and APM expect a weak Q1, each guiding to sales declines and breakeven-level EBITDA due to lower minerals demand and operational issues.

Source: Company, Anand Rathi Research (Reported GAAP numbers, adj. are Non-GAAP)

Fig 42 – Dow Chemical

($m)	CY25	CY24	y/y (%)
Revenue	39,968	42,964	-7.0
Adj. EBITDA	3,256	5,482	-40.6
Adj. EBITDA Margin (%)	8.1%	12.8%	-461 bps
Adj. EPS ($/ sh)	-0.93	1.71	-154.4

Comments/ Outlook

In 2026, Packaging & Specialty Plastics is expected to stabilise gradually amid weak pricing and maintenance headwinds, while Industrial Intermediates should see modest improvement from cost reductions. Performance Materials remains the relative bright spot, supported by lower fixed cost, improving coatings demand and firmer siloxane pricing. Packaging is expected to remain broadly stable aided by ~5% global ethylene capacity rationalisation; infrastructure demand improves outside North America on expected rate cuts; consumer demand weak in EMEAI but resilient in the US; mobility growth moderates globally.

Source: Company, Anand Rathi Research (Reported GAAP numbers, adj. are Non-GAAP)

Fig 43 – DIC Corp

(JPYbn)	CY25	CY24	y/y (%)	Comments/ Outlook
Revenue	1,052	1,071	-1.8	Delivered a resilient CY25 despite soft demand, with net sales of Yen1,052bn and operating income of Yen52bn, supported by high-value-added product momentum, firm pricing discipline, and a strong turnaround in Color & Display after structural reforms. In CY26, DIC anticipates a moderate recovery, driven by improving overseas demand, a richer high-value-added mix, and continued cost discipline (lifting sales to Yen1,100bn and operating income to Yen56bn. Segment-wise, Packaging & Graphic is set for modest growth with slight margin softness, Color & Display for the sharpest rebound on restructuring gains and better mix, and Functional Products for steady expansion underpinned by robust electronics demand and further mix upgrades.
EBITDA	109	96	14.2	
EBITDA Margin (%)	10.4%	8.9%	145 bps	
PAT	32	21	52.1	

Source: Company, Anand Rathi Research

Fig 44 – Eastman Chemical

($m)	CY25	CY24	y/y (%)	Comments/ Outlook
Revenue	8,752	9,382	-7	Delivered a tough CY25 with sales down to 7% y/y and Adjusted EBIT falling 28%, as Chemical Intermediates swung to losses on sharp pricing pressure and Asian competition, Fibers declined on destocking and capacity resets, and Advanced Materials and Additives & Functional Products faced weak demand in construction, consumer, and auto markets. Strong cash generation (~$1 bn), $100m cost savings, and $60m incremental earnings from Kingsport methanolysis partially cushioned the downturn. Eastman expects earnings improvement in CY26, supported by $125-150m further cost reduction, better manufacturing utilisation, and normalisation in Advanced Materials and AFP demand, guiding to EPS of $5.5–6, as macro conditions stabilise.
Adj. EBIT	930	1,298	-28.4	
Adj. EBIT Margin (%)	11.0	13.8	-321 bps	
Adj. EPS ($/ sh)	4.0	7.7	-46.7	

Source: Company, Anand Rathi Research (Reported GAAP numbers, Adj. are Non-GAAP)

Fig 45 – FMC

($m)	CY25	CY24	y/y (%)	Comments/ Outlook
Revenue	3,467	4,246	-18	CY26 recovery to be gradual: For CY26, FMC guides to revenue of $3.6-3.8bn (-5% y/y) and Adj. EBITDA of $670-730m (down 17% y/y) at the midpoint, citing continued competitive intensity, limited pricing upside and only modest volume recovery. New active ingredient sales are guided at $300-400m. Strategy shifts to mix and asset-light growth: FMC is prioritising new formulations, mixtures and next-gen actives, while accelerating licensing, outsourcing and asset monetisation to improve capital efficiency and BS strength. CTPR/ diamides now lifecycle-managed: FMC continues to manage diamides as post-patent products, prioritising volume, formulations and mix over pricing.
Adj EBITDA	843	903	-7	
Adj EBITDA Margin (%)	24%	21%	306 bps	
Adj. EPS	2.96	3.48	-15	

*Source: Company, Anand Rathi Research; (Reported GAAP numbers, *Adj. numbers are Non-GAAP)*

Fig 46 – Kureha

(JPYm)	9MFY26	9MFY25	y/y (%)	Comments/ Outlook
Revenue	162,015	177,973	-9	Revenue declined 9% y/y due to lower selling prices driven by PVDF mix and the prior withdrawal of the ML film business, while profit trends diverged—PVDF and PPS saw gains (write-down reversal, better pricing and costs), but PGA profits fell despite higher revenue because of production-related margin pressure. Full-year guidance remains unchanged, with PVDF expected to soften on weaker North American EV demand, though profits should improve on absence of inventory losses y/y; Iwaki capacity expansion remains on schedule for spring 2026, starting operations in Q4FY26 (i.e., 1QCY27). PGA growth continues despite US resin-plant inventory constraints amid production troubles. 2H impact is limited, while the next FY impact is under review.
Op Profit	9,428	12,800	-26	
Op Profit Margin (%)	5.8%	7.2%	-137 bps	
PAT	7,896	9,843	-20	

Source: Company, Anand Rathi Research

Spread Trends in Key Chemicals

Fig 47 - Ethyl Acetate spread declines on lower input prices



Source: Industry, Anand Rathi Research

Fig 48 - Acetic Anhydride spread falls on lower acetic prices



Source: Industry, Anand Rathi Research

Fig 49 – Ethyl Aceto Acetate spread largely stable



Source: Industry, Anand Rathi Research

Fig 50 – Methyl Aceto Acetate spread volatile



Source: Industry, Anand Rathi Research

Fig 51 – Pyridine – Beta Picoline spread moderates



Source: Industry, Anand Rathi Research

Fig 52 – Niacinamide spread marginally lower



Source: Industry, Anand Rathi Research

Fig 53 – MMA spread stable q/q



Source: Industry, Anand Rathi Research

Fig 54 – Phenol Acetone spread moderates



Source: Industry, Anand Rathi Research

Fig 55 – 2-4 D spread improves further



Source: Industry, Anand Rathi Research

Fig 56 – Epoxy Resin spread stable



Source: Industry, Anand Rathi Research

Fig 57 – R32 spreads improves on rising demand



Source: Industry, Anand Rathi Research

Fig 58 – R22 spread falls on price correction



Source: Industry, Anand Rathi Research

Fig 59 – PTFE spread firms up



Source: Industry, Anand Rathi Research

Fig 60 – Rubber Antioxidants spread pressure led by imports



Source: Industry, Anand Rathi Research

Fig 61 – BOPET spread inch up on RM supply cuts in China



Source: Industry, Anand Rathi Research

Fig 62 – BOPP relatively stable



Source: Industry, Anand Rathi Research

India's Chemical Import Trends

Fig 63 – R32 imports drop on rising domestic supplies



Source: Industry, Anand Rathi Research

Fig 64 – R134a imports moderate while prices rise



Source: Industry, Anand Rathi Research

Fig 65 – Fluorspar imports rise on AHF led demand



Source: Industry, Anand Rathi Research

Fig 66 – Acrylonitrile imports higher y/y, realisations flat



Source: Industry, Anand Rathi Research

Fig 67 – Phenol imports normalize in Q3



Source: Industry, Anand Rathi Research

Fig 68 – Acetone imports decline in Q3, prices lower



Source: Industry, Anand Rathi Research

Fig 69 – Soda Ash imports trend higher; ADD not confirmed



Source: Industry, Anand Rathi Research

Fig 70 – Aniline imports surge on Aarti's MMA led demand



Source: Industry, Anand Rathi Research

Fig 71 – BOPET imports decline q/q though still elevated



Source: Industry, Anand Rathi Research

Fig 72 – BOPP imports drop after JPL fire led surge in Q2.



Source: Industry, Anand Rathi Research

Fig 73 – MEG imports remain stable



Source: Industry, Anand Rathi Research

Fig 74 – PTA imports higher in Q3



Source: Industry, Anand Rathi Research

Fig 75 – TiO2 imports moderate on downstream seasonality



Source: Industry, Anand Rathi Research

Fig 76 – Epichlorohydrin imports rise on new Epoxy capacity



Source: Industry, Anand Rathi Research

Fig 77 – Phosphoric Acid imports inch up, prices rise



Source: Industry, Anand Rathi Research

Fig 78 – Crude Palm Oil import prices firm up



Source: Industry, Anand Rathi Research

Fig 79 – PVC Susp. witnessing higher imports from China



Source: Industry, Anand Rathi Research

Fig 80 – TDI imports retreat after ADD review-driven spike



Source: Industry, Anand Rathi Research

Fig 81 – Acetic Acid imports moderate in Q3, after a surge in last couple of qtrs



Source: Industry, Anand Rathi Research

Fig 82 – Global Chemicals Price Trends

Commodity	Curr/Unit	Latest Price	Fnightly Chg (%)	Change (m/m %)	Q4FY26 (Avg QTD)	Q3FY26 (Avg)	Change (q/q %)	Q4FY25 (Avg)	Change (y/y %)
Chlor-Alkali and chlorine downstream									
Caustic Soda	USD/MT	405	3%	0%	405	445	-9%	529	-23%
Soda Ash	USD/MT	151	-1%	-1%	154	152	1%	181	-15%
Ethylene Dichloride	USD/MT	135	29%	29%	111	113	-2%	188	-41%
Vinyl Chloride Monomer	USD/MT	485	11%	17%	433	507	-15%	581	-25%
Epichlorohydrin	CNY/MT	12,250	0%	2%	12,114	11,749	3%	9,300	30%
PVC	USD/MT	740	9%	16%	663	650	2%	748	-11%
PVC Suspension	USD/MT	740	6%	9%	680	696	-2%	768	-11%
Methanol downstream									
Methanol	USD/MT	295	-3%	-5%	304	318	-5%	334	-9%
Acetic Acid	CNY/MT	2,640	2%	-6%	2,686	2,440	10%	2,805	-4%
Ethyl Acetate	CNY/MT	5,425	0%	0%	5,391	5,304	2%	5,399	0%
Formaldehyde	INR/KG	28	0%	0%	28	28	-2%	35	-20%
Formic Acid	INR/KG	80	0%	-6%	82	84	-3%	85	-4%
Vinyl Acetate	CNY/MT	5,900	0%	0%	5,908	5,722	3%	5,884	0%
MTBE	USd/Gal	197	-2%	10%	189	220	-14%	221	-15%
Cumene downstream									
Phenol	USD/MT	833	2%	11%	778	779	0%	941	-17%
Acetone	CNY/MT	4,825	-2%	2%	4,677	4,305	9%	6,318	-26%
Acrylonitrile Butadiene Styrene (ABS)									
Acrylonitrile	USD/MT	1,325	0%	0%	1,325	1,325	0%	1,481	-11%
Butadiene	USD/MT	1,215	0%	8%	1,120	817	37%	1,323	-15%
Styrene	USD/MT	1,010	-5%	2%	987	844	17%	1,073	-8%
ABS	USD/MT	1,310	5%	7%	1,246	1,240	1%	1,477	-16%
Polypropylene (PP) and Polyethylene Terephthalate (PET)									
PP	USD/MT	890	2%	3%	866	870	0%	1,000	-13%
PET	CNY/MT	6,335	0%	2%	6,220	5,777	8%	6,250	0%
PTA	USD/MT	690	-1%	3%	687	644	7%	680	1%
MEG	USD/MT	445	-5%	-1%	459	479	-4%	555	-17%
Polyethylene (PE) and Polystyrene (PS)									
HDPE	USD/MT	900	2%	2%	879	894	-2%	984	-11%
LDPE	USD/MT	1,040	0%	2%	1,023	1,043	-2%	1,183	-13%
LLDPE	USD/MT	870	2%	4%	849	879	-3%	1,013	-16%
Polystyrene	USD/MT	1,200	3%	6%	1,151	1,151	0%	1,357	-15%
Others									
Caprolactam	CNY/MT	9,925	1%	6%	9,562	8,700	10%	10,525	-9%
Nylon 6	INR/KG	200	0%	0%	200	200	0%	149	34%
Fluorspar 97%	CNY/MT	3,390	0%	1%	3,366	3,497	-4%	3,658	-8%
Acrylic Acid	USD/MT	784	0%	2%	765	801	-4%	931	-18%
Maleic Anhydride	USD/MT	672	0%	1%	660	660	0%	804	-18%
Phthalic Anhydride	CNY/MT	6,050	-1%	-4%	6,125	5,704	7%	7,104	-14%
Titanium Dioxide	USD/MT	2,012	0%	1%	1,993	1,932	3%	2,072	-4%
Linear Alkylbenzene	USD/MT	1,650	-1%	1%	1,651	1,647	0%	1,622	2%
TDI	CNY/MT	14,500	0%	4%	14,150	13,951	1%	13,297	6%
Ethanol	USD/Gallon	1.59	9%	4%	1.55	1.71	-9%	1.54	0%
Rock Phosphate	USD/ST	203	0%	0%	203	203	0%	203	0%
Phosphoric Acid	USD/MT	1,290	0%	0%	1,290	1,287	0%	1,060	22%
Ammonia	USD/MT	670	1%	5%	659	662	0%	583	13%
Sulfuric Acid	CNY/MT	1,030	6%	12%	956	834	15%	463	106%
Building Blocks									
Benzene	USD/MT	785	0%	11%	740	679	9%	883	-16%
Toluene (Korea)	USD/MT	720	-3%	5%	702	665	6%	770	-9%
Ethylene	USD/MT	690	1%	-2%	700	748	-6%	924	-24%
Propylene	USD/MT	840	1%	6%	798	753	6%	858	-7%
Feedstocks									
Crude Oil (Brent)	USD/BBL	72	5%	12%	66	63	5%	75	-12%
Indonesian Coal - 6322Kcal	USD/MT	106	0%	3%	104	104	0%	123	-15%
Naphtha	USD/MT	613	2%	8%	573	563	2%	658	-13%
Natural Gas	USD/MMBtu	3.0	-11%	-40%	3.8	4.1	-7%	4	-3%
Indonesian Coal - 6322Kcal	USD/MT	106	0%	3%	104	104	0%	123	-15%
Oleochemical Feedstocks									
Crude Palm Oil	MYR/MT	4,044	-2%	-2%	4,061	4,174	-3%	4,715	-14%
Palm Kernel Oil	MYR/MT	7,193	-2%	0%	7,120	7,243	-2%	7,674	-7%
Rapeseed Oil	EUR/MT	1,086	2%	4%	1,057	1,100	-4%	1,088	-3%
Canola Oil	BRL/MT	8,800	1%	-1%	8,887	9,534	-7%	9,792	-9%
Olive Oil	EUR/MT	4,433	6%	5%	4,232	4,542	-7%	4,066	4%
Mustard Oil	INT/Tin	2,290	-5%	-5%	2,366	2,378	0%	2,123	11%
Castor Oil	USD/MT	1,958	0%	-1%	1,964	1,966	0%	1,865	5%
Sunflower Oil	USD/MT	1,430	1%	1%	1,403	1,329	6%	1,206	16%
Soyabean Oil	BRL/MT	5,916	1%	-1%	5,986	6,413	-7%	6,018	-1%
Freight									
Baltic Dry Index (RHS)	Index	2,043	6%	16%	1,876	2,136	-12%	1,122	67%
Containerized Freight Index (Shanghai)	Index	1,251	-1%	-20%	1,449	1,405	3%	1,813	-20%
Currencies									
USDINR		91.0	0%	-1%	90.8	89.1	2%	87	5%
CNYINR		13.2	1%	0%	13.1	12.6	4%	12	10%
EURUSD		1.2	0%	0%	1.2	1.2	1%	1	12%

Source: Bloomberg, Anand Rathi Research

Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps, Mid Caps & Small Caps as described in the Ratings Table below:

Ratings Guide (12 months)	Buy	Hold	Sell
Large Caps (Top 100 companies)	>15%	0-15%	<0%
Mid Caps (101st-250th company)	>20%	0-20%	<0%
Small Caps (251st company onwards)	>25%	0-25%	<0%

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015, BSE Enlistment Number – 5048 date of Regn 25 July 2024) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd (BSE), National Stock Exchange of India Ltd. (NSEIL),Multi Commodity Exchange of India Limited (MCX),National Commodity & Derivatives Exchange Limited (NCDEX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. (CDSL), ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. ARSSBL does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding taxation aspects of any potential investment.

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No

NOTICE TO US INVESTORS:

This research report is the product of Anand Rathi Share and Stock Brokers Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated person(s) of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances, and trading securities held by a research analyst account.

Research reports are intended for distribution only to Major U.S. Institutional Investors as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act of 1934 (the Exchange Act) and interpretations thereof by the U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this research report is not a Major U.S. Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated, and/or transmitted onward to any U.S. person which is not a Major U.S. Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major U.S. Institutional Investors, Anand Rathi Share and Stock Brokers Limited has entered into a Strategic Partnership and chaperoning agreement with a U.S. registered broker-dealer: Banc Trust Securities USA. Transactions in securities discussed in this research report should be affected through Banc Trust Securities USA.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

As of the publication of this report, ARSSBL does not make a market in the subject securities.

Registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Additional information on recommended securities/instruments is available on request.

Compliance officer: Deepak Kedia, email id: deepakkedia@rathi.com, Contact no. +91 22 6281 7000. **Grievance officer:** Madhu Jain, email id: grievance@rathi.com, Contact no. +91 22 6281 7191

ARSSBL registered address: Express Zone, A Wing, 10th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.

Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.